SPOTLIGHT: Biogen CEO: Pharma too wimpy to deal


Biogen Idec CEO to Big Pharma: You just didn't have the guts to make a deal. In an interview with the Boston Globe this week, Biogen honcho Jim Mullen said major drug makers are more conservative than smaller biotechs like Biogen and its crosstown neighbor Genzyme. "They never would have pursued some of the drugs we pursued," Mullen said. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.